EMA challenged over "revolving door" involving former head
This article was originally published in SRA
Executive Summary
The European Medicines Agency's decision to allow its former executive director, Thomas Lönngren, to join private sector companies just weeks after leaving his post at the agency has been criticised by public health and transparency campaigners, who are concerned "that rules regarding conflicts of interest may not have been respected" in this case1.
You may also be interested in...
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.
Global Medtech Guidance Tracker: March 2024
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-nine documents have been posted on the tracker since its last update.